232 related articles for article (PubMed ID: 17424750)
21. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
Jirasiritham S; Khunprakant R; Techawathanawanna N; Jirasiritham S; Mavichak V
Transplant Proc; 2010 Apr; 42(3):987-9. PubMed ID: 20430222
[TBL] [Abstract][Full Text] [Related]
22. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
[TBL] [Abstract][Full Text] [Related]
23. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results.
Kaufman DB; Leventhal JR; Gallon LG; Parker MA
Am J Transplant; 2006 Feb; 6(2):331-9. PubMed ID: 16426317
[TBL] [Abstract][Full Text] [Related]
24. Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis.
Sampaio MS; Chopra B; Sureshkumar KK
Transplantation; 2017 Oct; 101(10):2527-2535. PubMed ID: 28475563
[TBL] [Abstract][Full Text] [Related]
25. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.
Villanueva ME; Muñoz AS; Casasola CC; Africa JB; Danguilan RA; Ona ET
Transplant Proc; 2008 Sep; 40(7):2222-5. PubMed ID: 18790198
[TBL] [Abstract][Full Text] [Related]
26. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.
Magliocca JF; Knechtle SJ
Transpl Int; 2006 Sep; 19(9):705-14. PubMed ID: 16918530
[TBL] [Abstract][Full Text] [Related]
27. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H).
Gallon L; Gagliardini E; Benigni A; Kaufman D; Waheed A; Noris M; Remuzzi G
Clin J Am Soc Nephrol; 2006 May; 1(3):539-45. PubMed ID: 17699257
[TBL] [Abstract][Full Text] [Related]
28. Campath induction for kidney transplantation: report of 297 cases.
Ortiz J; Palma-Vargas J; Wright F; Bingaman A; Agha I; Rosenblatt S; Foster P
Transplantation; 2008 Jun; 85(11):1550-6. PubMed ID: 18551058
[TBL] [Abstract][Full Text] [Related]
29. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation.
Gruessner RW; Kandaswamy R; Humar A; Gruessner AC; Sutherland DE
Transplantation; 2005 May; 79(9):1184-9. PubMed ID: 15880067
[TBL] [Abstract][Full Text] [Related]
30. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.
Tan HP; Kaczorowski DJ; Basu A; Unruh M; McCauley J; Wu C; Donaldson J; Dvorchik I; Kayler L; Marcos A; Randhawa P; Smetanka C; Starzl TE; Shapiro R
Am J Transplant; 2006 Oct; 6(10):2409-17. PubMed ID: 16889606
[TBL] [Abstract][Full Text] [Related]
31. Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab.
Lick SD; Beckles DL; Piovesana G; Vaidya S; Indrikovs A; Barbagelata NA; Valentine V
Ann Thorac Surg; 2011 Oct; 92(4):1428-34. PubMed ID: 21855854
[TBL] [Abstract][Full Text] [Related]
32. How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation?
Knechtle SJ
Nat Clin Pract Nephrol; 2005 Dec; 1(2):74-5. PubMed ID: 16932370
[No Abstract] [Full Text] [Related]
33. The use of Campath-1H as induction therapy in renal transplantation: preliminary results.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roohipour R; Carreno MR; Roth D; Ruiz P; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
Transplantation; 2004 Aug; 78(3):426-33. PubMed ID: 15316372
[TBL] [Abstract][Full Text] [Related]
34. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.
Barth RN; Janus CA; Lillesand CA; Radke NA; Pirsch JD; Becker BN; Fernandez LA; Thomas Chin L; Becker YT; Odorico JS; D'Alessandro AM; Sollinger HW; Knechtle SJ
Transpl Int; 2006 Nov; 19(11):885-92. PubMed ID: 17018123
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation.
Taber DJ; Weimert NA; Henderson F; Lin A; Bratton CF; Chavin KD; Baliga PK
Transplant Proc; 2008 Dec; 40(10):3401-7. PubMed ID: 19100399
[TBL] [Abstract][Full Text] [Related]
36. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States.
Gill J; Sampaio M; Gill JS; Dong J; Kuo HT; Danovitch GM; Bunnapradist S
Clin J Am Soc Nephrol; 2011 May; 6(5):1168-78. PubMed ID: 21511836
[TBL] [Abstract][Full Text] [Related]
37. Cancer risk with alemtuzumab following kidney transplantation.
Puttarajappa C; Yabes J; Bei L; Shah N; Bernardo J; McCauley J; Basu A; Tan H; Shapiro R; Unruh M; Wu C
Clin Transplant; 2013; 27(3):E264-71. PubMed ID: 23480032
[TBL] [Abstract][Full Text] [Related]
38. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
Kirsch BM; Haidinger M; Zeyda M; Böhmig GA; Tombinsky J; Mühlbacher F; Watschinger B; Hörl WH; Säemann MD
Transpl Immunol; 2006 Nov; 16(3-4):254-7. PubMed ID: 17138063
[TBL] [Abstract][Full Text] [Related]
39. Kidney transplantation achievements in Mongolia.
Jambaljav L; Nyamsuren D; Byambadash B; Ganbold L
Transplant Proc; 2010 Apr; 42(3):791-2. PubMed ID: 20430173
[TBL] [Abstract][Full Text] [Related]
40. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.
Knechtle SJ; Pascual J; Bloom DD; Torrealba JR; Jankowska-Gan E; Burlingham WJ; Kwun J; Colvin RB; Seyfert-Margolis V; Bourcier K; Sollinger HW
Am J Transplant; 2009 May; 9(5):1087-98. PubMed ID: 19344431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
